Repligen (NASDAQ:RGEN) Reaches New 1-Year High at $311.29

Repligen Co. (NASDAQ:RGEN) shares reached a new 52-week high on Tuesday . The company traded as high as $311.29 and last traded at $306.05, with a volume of 545535 shares trading hands. The stock had previously closed at $306.90.

A number of equities research analysts recently weighed in on RGEN shares. Craig Hallum raised their price target on shares of Repligen from $251.00 to $258.00 and gave the company a “buy” rating in a report on Wednesday, July 28th. Stephens raised their price objective on shares of Repligen from $255.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 20th. Finally, KeyCorp raised their price objective on shares of Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a report on Friday, September 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Repligen currently has an average rating of “Buy” and a consensus target price of $262.17.

The stock has a market capitalization of $17.19 billion, a P/E ratio of 174.92 and a beta of 0.90. The company’s 50-day moving average is $261.43 and its two-hundred day moving average is $218.06.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Monday, July 26th. The biotechnology company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.27. The firm had revenue of $162.96 million for the quarter, compared to the consensus estimate of $144.24 million. Repligen had a net margin of 19.65% and a return on equity of 9.21%. Repligen’s quarterly revenue was up 86.3% compared to the same quarter last year. During the same period last year, the firm posted $0.42 EPS. On average, research analysts predict that Repligen Co. will post 2.76 earnings per share for the current fiscal year.

In other news, Director Karen A. Dawes sold 274 shares of Repligen stock in a transaction that occurred on Tuesday, September 14th. The shares were sold at an average price of $294.26, for a total value of $80,627.24. Following the transaction, the director now directly owns 93,908 shares of the company’s stock, valued at $27,633,368.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 780 shares of Repligen stock in a transaction that occurred on Wednesday, August 4th. The stock was sold at an average price of $250.50, for a total transaction of $195,390.00. The disclosure for this sale can be found here. Insiders have sold a total of 52,154 shares of company stock worth $14,144,680 over the last 90 days. 1.20% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Northern Trust Corp grew its position in Repligen by 8.9% during the first quarter. Northern Trust Corp now owns 447,905 shares of the biotechnology company’s stock valued at $87,076,000 after purchasing an additional 36,532 shares in the last quarter. US Bancorp DE grew its position in Repligen by 14.3% during the second quarter. US Bancorp DE now owns 7,267 shares of the biotechnology company’s stock valued at $1,451,000 after purchasing an additional 908 shares in the last quarter. TD Asset Management Inc. grew its position in Repligen by 25.0% during the first quarter. TD Asset Management Inc. now owns 6,595 shares of the biotechnology company’s stock valued at $1,282,000 after purchasing an additional 1,321 shares in the last quarter. Principal Financial Group Inc. grew its position in Repligen by 47.0% during the first quarter. Principal Financial Group Inc. now owns 224,174 shares of the biotechnology company’s stock valued at $43,582,000 after purchasing an additional 71,722 shares in the last quarter. Finally, Securian Asset Management Inc grew its position in Repligen by 2.1% during the first quarter. Securian Asset Management Inc now owns 4,811 shares of the biotechnology company’s stock valued at $935,000 after purchasing an additional 100 shares in the last quarter. 83.82% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile (NASDAQ:RGEN)

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

See Also: Capital gains and your 401(k) or IRA

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.